GHK-Cu vs Nonapeptide-1
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Copper Peptide, Glycyl-L-histidyl-L-lysine copper
GHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide (glycyl-L-histidyl-L-lysine) found in blood plasma, saliva and urine, whose levels decline with age. It is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. It is not an FDA-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies.
Also: Melanostatine 5, Melanostatine-5
Nonapeptide-1, sold as Melanostatine 5, is a nine-amino-acid synthetic peptide built to block alpha-MSH, the hormone that tells pigment cells to make melanin. It goes into brightening and dark-spot products as a gentler alternative to harsh lighteners. It is a cosmetic ingredient, not an FDA-approved drug, and there is no independent peer-reviewed clinical trial of it on its own.
Key Comparison Insights
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
- GHK-Cu has stronger research evidence (Human Trials) compared to Nonapeptide-1 (Limited Research).
Detailed Comparison
| Attribute | GHK-Cu | Nonapeptide-1 |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | GHK has a strong affinity for copper(II) ions and forms the GHK-Cu complex, which is thought to deliver copper to cells for copper-dependent processes such as connective-tissue formation and antioxidant defense. Its most striking documented activity is broad gene-expression modulation: in cultured human cells, GHK shifts the expression of a large fraction of genes, tending to upregulate tissue-repair genes and downregulate some inflammatory pathways. It stimulates fibroblasts to produce collagen and other extracellular-matrix proteins, supports keratinocyte and blood-vessel activity, and shows antioxidant and anti-inflammatory effects in lab models. Importantly, the copper-binding hypothesis does not fully explain these gene effects, and researchers note the precise mechanism is not yet fully understood. | When skin is hit by UV, it releases alpha-MSH, which binds the MC1R receptor on melanocytes and switches on tyrosinase, the enzyme that makes melanin. Nonapeptide-1 is designed to sit in that receptor without switching it on, a competitive antagonist, so less of the tanning and pigment signal gets through. In cell studies it binds MC1R with high affinity and blocks alpha-MSH-driven melanosome dispersion at nanomolar levels, and it lowered tyrosinase and related pigment genes in human melanocytes. It is essentially the opposite of melanotan I and afamelanotide, which activate the same receptor to darken skin. The big unknown, as with most cosmetic peptides, is how much reaches melanocytes through intact skin. |
| Common Dosing | 1-2 mg daily systemically, or 0.05% in cosmetic formulations Once daily | Low percentage in a brightening serum Once or twice daily |
| Administration | Subcutaneous injection or topical application | Topical (serums, creams) |
| Typical Duration | Varies by application | Brightening claims are usually judged over 8 to 12 weeks; ongoing use |
| Best Time to Take | Evening (for skin/recovery) | Morning (under sunscreen) and/or evening |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Much of the mechanistic and efficacy evidence is from cell culture and animal studies. In animals, GHK and GHK-containing dressings improved wound contraction, granulation tissue and collagen deposition in rabbit and rat wounds, and showed protective effects in lung-injury models. In cells, GHK increases collagen, elastin and growth-factor production by fibroblasts and protects keratinocytes from UV damage. Human evidence exists but is limited to small cosmetic trials: facial-cream and eye-cream studies in modest numbers of women (for example a 71-subject facial study and a 41-subject eye-cream study) reported improvements in skin density, thickness and wrinkle appearance. These trials are small and focused on topical skin endpoints, so they do not establish injected or systemic benefits, and there are no large independent randomized trials. Honest summary: strong lab and animal data plus encouraging small topical human studies, but evidence for injected use is preliminary. | The evidence is thin and mostly commercial. Receptor binding and anti-pigment effects come from cell work and supplier data sheets. In a 2022 paper in Postepy Dermatologii i Alergologii (Chen and colleagues), nonapeptide-1 was used as a reference MC1R blocker in UVA-exposed human melanocytes and keratinocytes, where it reduced pigment pathway activity, but the study's focus was tea polyphenols, not the peptide. Ingredient databases describe the human data as small and manufacturer-generated. You will see claims online of a 12-week, 40-person trial where a cream with this peptide matched 4 percent hydroquinone for melasma, but we could not find a published, citable version, and even then it was a multi-ingredient cream. Fair summary: a well-designed molecule with a clear mechanism in cells, and very little real-world proof. Sunscreen still does more for dark spots than any single brightening peptide. |
Frequently Asked Questions: GHK-Cu vs Nonapeptide-1
What is the difference between GHK-Cu and Nonapeptide-1?
GHK-Cu is a skin & hair peptide that ghk-cu is the copper(ii) complex of ghk, a naturally occurring human tripeptide (glycyl-l-histidyl-l-lysine) found in blood plasma, saliva and urine, whose levels decline with age. it is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. it is not an fda-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies. Nonapeptide-1 is a skin & hair peptide that nonapeptide-1, sold as melanostatine 5, is a nine-amino-acid synthetic peptide built to block alpha-msh, the hormone that tells pigment cells to make melanin. it goes into brightening and dark-spot products as a gentler alternative to harsh lighteners. it is a cosmetic ingredient, not an fda-approved drug, and there is no independent peer-reviewed clinical trial of it on its own. The main differences lie in their mechanisms of action and clinical applications.
Which is better, GHK-Cu or Nonapeptide-1?
Neither is universally "better" - the choice depends on your specific goals. GHK-Cu is typically used for skin & hair purposes, while Nonapeptide-1 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can GHK-Cu and Nonapeptide-1 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using GHK-Cu and Nonapeptide-1 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.